Susceptibility pattern of Mycobacterium tuberculosis over a period of five years at Indus Hospital and Health Network, Karachi, Pakistan

2021 ◽  
Vol 38 (ICON-2022) ◽  
Author(s):  
Nazia Khursheed ◽  
Sunil Asif ◽  
Safia Bano ◽  
Maria Mushtaq Ali ◽  
Fareeha Adnan

Objective: To determine the susceptibility pattern and frequency of isolation of multidrug, pre-extensively drug and extensively drug resistant TB in a tertiary care hospital in Karachi, Pakistan. Method: A cross-sectional study was designed. Samples received in the lab were processed for growth and sensitivity testing of Mycobacterium tuberculosis. Isolation of MTB was done on Mycobacteria growth indicator tube (MGIT) followed by identification using MPT64. Samples were than evaluated for drug sensitivity against first and second-line antimycobacterial drugs. Statistical analysis was performed using SPSS version 24.0. Results: Of the 20014 samples received, 23.1% were identified as Mycobacterium tuberculosis. Drug sensitivity testing was performed on 95.9% isolates. Fifty-two percent samples were from males and 48% female patients. The study found statistically non-significant relationship between gender and likelihood of disease with drug-resistant (DR)-MTB organisms. The rate of isolation of MDR-TB was highest (43%) among ages 25-55 years and previously treated patients compared to newly diagnosed patients (62% vs 36%). Among MTB positive samples, 91.5% were pulmonary while 8.5% were extrapulmonary samples. Extrapulmonary samples were more likely to be sensitive to antimycobacterial drugs. The highest resistance was observed against Isoniazid (pulmonary=58%; extrapulmonary=12.7%), Rifampicin (pulmonary=58.7%; extrapulmonary=8.2%), and Levofloxacin (pulmonary=29.2%; extrapulmonary=20%). Conclusion: A considerable number of drug resistant tuberculosis cases were identified in the present study. It is essential to develop further strategies to reduce the spread of this disease. doi: https://doi.org/10.12669/pjms.38.ICON-2022.5778 How to cite this:Khursheed N, Asif S, Bano S, Ali MM, Adnan F. Susceptibility pattern of Mycobacterium tuberculosis over a period of five years at Indus Hospital and Health Network, Karachi, Pakistan. Pak J Med Sci. 2022;38(2):399-404.  doi: https://doi.org/10.12669/pjms.38.ICON-2022.5778 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

2016 ◽  
Vol 22 (1) ◽  
pp. 78
Author(s):  
Muhammad Khalid Ch ◽  
Muhammad Saqib Saeed ◽  
Rizwan Iqbal ◽  
Akhtar Ali

<p><strong>Abstract</strong></p><p><strong>Background:  </strong>Tuberculous pleurisy is a common extrapulmonary manifestation and is second to tuberculous lymphadenitis. Due to its paucibacillary in origin, its diagnosis is a challenge. Furthermore, it is also complicated by the emergence of MDR. Gene Xpert MTB/RIF is a new rapid promising innovation for the detection of mycobacterium tuberculosis and its resistance to Rifampicin, giving result within two hours.</p><p><strong>Objective:  </strong>To evaluate the diagnostic role of Gene Xpert MTB/RIF in suspected cases of tuberculous pleurisy.</p><p><strong>Study Design:  </strong>Cross sectional study.</p><p><strong>Study Setting:  </strong>Institute of Chest Medicine Mayo Hospital – a Tertiary Care Hospital affiliated with King Edward Medical University, Lahore.</p><p><strong>Methodology:  </strong>The study group, one hundred (M-60 and F-40) cases having exudative, predominantly lymphocytic pleural effusion with strong suspicion of tuberculous in origin were enrolled randomly for Gene Xpert MTB / RIF.</p><p><strong>Results:  </strong>Among one hundred study cases, Gene Xpert detected mycobacterium tuberculosis in 12(12%) cases [M-8 (13.3%) and F-4 (10%)]. Resistance to Rifampacin was detected in 6 (6%) cases [M-2 (3.3%) and F-4 (10%)].</p><p><strong>Conclusion:  </strong>Gene Xpert MTB/RIF is a useful new rapid promising technique to diagnose tuberculous pleurisy. Although at present it has limited availability and utility.</p><p><strong>Key Words:  </strong>Gene Xpert. MTB – Mycobacterium tuberculosis. RIF – Rifampacin. TB – Tuberculosis. MDR – Multidrug resistance.</p>


2021 ◽  
Vol 7 (4) ◽  
pp. 207-214
Author(s):  
Dr. Neelima Pantagada ◽  
◽  
Dr. Praveen Kavoori ◽  

Introduction: Chronic suppurative otitis media is a chronic infection of the middle ear and mastoidcavity which if not treated leads to partial or total loss of hearing and even life-threateningcomplications like meningitis and Intracranial abscess. Hence it is important to treat the persistentear discharge in CSOM according to the antimicrobial sensitivity of the organism isolated. Methods:This is a prospective cross-sectional study done in 135 clinically diagnosed patients of CSOM at GSLmedical college and General Hospital, Rajamundry, Andhra Pradesh from May 2019 to October 2019.Sterile swabs were used to collect pus from discharging ear and were inoculated onto Blood andMacConkey agar for 24-48 hrs, and identification of organisms was done by using standardbiochemical reactions and antibiotic sensitivity testing done by using modified Kirby- Bauer methodas per CLSI guidelines. Results: A total of 156 strains were isolated from 135 patients in thepresent study of which Pseudomonas aeruginosa and Staphylococcus aureus were amongst the mostisolated pathogens in culture. Imipenem showed the most sensitivity against Pseudomonas,subsequently levofloxacin and piperacillin. Linezolid was the most sensitive versus Staphylococcusensued by ciprofloxacin and cloxacillin. Conclusions: In the present study of Chronic suppurativeotitis media patients, Pseudomonas and Staphylococcus were highly prevalent and showed increasedresistance to beta-lactams and commonly used antimicrobial drugs. Antimicrobials like imipenem,piperacillin, and quinolones are effective against most cases of chronic suppurative otitis media


Vacunas ◽  
2020 ◽  
Vol 21 (2) ◽  
pp. 95-104 ◽  
Author(s):  
Y.M. AlGoraini ◽  
N.N. AlDujayn ◽  
M.A. AlRasheed ◽  
Y.E. Bashawri ◽  
S.S. Alsubaie ◽  
...  

Author(s):  
Nandini Chatterjee ◽  
Supratick Chakraborty ◽  
Mainak Mukhopadhyay ◽  
Sinjon Ghosh ◽  
Bikramjit Barkandaj ◽  
...  

2020 ◽  
Vol 32 (1) ◽  
Author(s):  
Nearmeen M. Rashad ◽  
Marwa G. Amer ◽  
Waleed M. Reda Ashour ◽  
Hassan M. Hassanin

Abstract Background Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system with varied clinical features. Disease-modifying drugs (DMDs) of MS associated with different types of thyroiditis. In this cross-sectional study, we aimed to assess the prevalence of thyroid dysfunction in MS and to investigate the association between DMDs and the risk of thyroiditis in MS. A cross-sectional study included 100 patients with relapsing-remitting multiple sclerosis (RRMS) in relapse, and the diagnosed was according to revised McDonald’s criteria 2010. Results Our results revealed that the prevalence of thyroiditis was 40%; autoimmune (34%) and infective (6%) among patients with RRMS in relapse and cerebellar symptoms were significantly higher in patients with thyroiditis compared to patients without thyroiditis. Regarding the association between DMDs and thyroiditis, the prevalence of patients treated with interferon-beta-1b was higher in MS patients with thyroiditis compared to MS patients without thyroiditis. However, the prevalence of patients treated with interferon-beta-1a was lower in MS patients with thyroiditis compared to MS patients without thyroiditis. In addition, we found CMV infection was more common in patients treated by interferon beta-1b and candida infection was common in patients treated by fingolimod. Conclusions Thyroiditis is commonly observed in patients with RRMS in relapse and higher prevalence of patients treated with interferon-beta-1b which is commonly associated with thyroiditis and CMV infection; however, candida thyroid infection was common in MS patients treated by fingolimod.


Sign in / Sign up

Export Citation Format

Share Document